英文标题:EGFR Inhibitors Combined with Intrathoracic Perfusion Manages Malignant Pleural Effusion in EGFR-Mutated Metastatic Lung Adenocarcinoma 中文标题:EGFR抑制剂联合胸腔内灌注治疗EGFR突变转移性肺腺癌的恶性胸腔积液 讲者:W. Huang(...
5. Mok, T. et al. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722....
[1]PASSARO A, JäNNE P A, MOK T, et al. Overcoming therapy resistance in EGFR-mutant lung cancer [J]. Nature Cancer, 2021, 2(4): 377-91.[2]WU Y L, PLANCHARD D, LU S, et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small...
[1]AKAMATSU H, TOI Y, HAYASHI H, et al. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clin...
5. Mok, T. et al.Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol...
EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study[J]. Mol Cancer. 2023 Aug 5;22(1):124. [12] J Yang,et al.Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberran...
[5] Kuijpers C C H J , Hendriks L E L , Derks J L , et al. Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer[J]. Lung Cancer, 2018:S0169500218303702. ...
EGFR（Epidermal Growth Factor Receptor，表皮生长因子受体）基因突变是非小细胞肺癌（non-small-cell lung cancer, NSCLC）中最常见的激活突变。目前被批准用于EGFR突变晚期NSCLC的靶向药物包括一代、二代和三代。随机对照研究显示，奥希替尼作为三代EGFR靶向药相比传统的一代显示出更佳生存获益[1]，无疾病进展生存期...
[8]Shun Lu, Jianying Zhou, Hong Jian, et al. Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomized phase III study. 2022 ESMO Asia, LBA6. ...
[6] Jonathan W. Goldman, Hidehito Horinouchi, Byoung Chul Cho,Jonathan W,et al.Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC). ...